- Home
- HLF vs TRVI Comparison
HLF vs TRVI Comparison
Compare HLF & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HLF | TRVI |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 939.1M | 1.4B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HLF | TRVI |
|---|---|---|
| Price | $14.66 | $12.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $14.00 | ★ $20.59 |
| AVG Volume (30 Days) | 2.4M | ★ 2.4M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.95 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $4,961,900,000.00 | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $4.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.04 | $3.43 |
| 52 Week High | $15.00 | $14.39 |
Technical Indicators
Market Signals| Indicator | HLF | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 77.64 | 55.32 |
| Support Level | $11.61 | $12.92 |
| Resistance Level | $13.35 | $14.39 |
| Average True Range (ATR) | 0.66 | 0.87 |
| MACD | 0.18 | -0.03 |
| Stochastic Oscillator | 90.28 | 57.94 |
Price Performance
Historical ComparisonAbout HLF Herbalife Ltd.
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.